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Original Article
Associations of Demographic Factors
and Tobacco Use With Progesterone
and Estradiol During Pregnancy
Kristin Ashford, PhD1, Emily Rayens, BS, BA2,
Amanda T. Wiggins, PhD1, Mary Kay Rayens, PhD1,3,
Molly Malany Sayre, PhD4 , and John O’Brien, MD5
Abstract
Objective: To evaluate the association of biochemically validated prenatal tobacco use with serum progesterone and
estradiol in the second trimester of pregnancy, controlling for demographic and personal factors.
Study design: This secondary analysis of a multicenter longitudinal study included 114 women with singleton
pregnancies. Multiple regression analysis assessed whether prenatal tobacco use was related to hormone levels
during the second trimester, controlling for covariates (age, body mass index, and race or ethnicity, with gestational
age added to subsequent models).
Result: In the initial regressions, tobacco users had significantly lower progesterone level compared with nonsmokers
(p¼ .037), while estradiol was unrelated to prenatal tobacco use. Women with greater body mass index also had
significantly lower progesterone (p¼ .028), but body mass index was unrelated to estradiol. With gestational age as an
additional covariate, prenatal tobacco use was no longer a significant predictor of progesterone, but both body mass
index and gestational age were significant (F¼ 10.6, p< .001, R2¼ 0.35). For estradiol, the overall regression of
estradiol on age, body mass index, and race or ethnicity was not significant (F¼ 1.2, p¼ .31). With gestational age
added to the model, the overall model was significant (F¼ 7.2, p< .001, R2¼ 0.27).
Conclusion: This study provides additional evidence that prenatal tobacco use may influence lower serum proges-
terone during the second trimester. This is of particular concern given the link between depressed progesterone activity
and risk for preterm birth.
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Introduction
Smoking during pregnancy increases the risk of adverse
outcomes, including impaired placental attachment and
function, miscarriage, delayed fetal lung and brain devel-
opment, stillbirth, preterm birth, low birth weight, and
Sudden Infant Death Syndrome (Centers for Disease
Control and Prevention, 2016; Dietz et al., 2010).
Consistent with the increased likelihood of adverse
events, smoking during pregnancy results in higher
neonatal medical costs: In the United States, smoking-
attributable health-care costs for neonates are
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approximately $366 million per year (Maurice, Kahende,
Trosclair, Dube, & Husten, 2008). This is a major public
health concern given that 12% of women in the United
States report smoking during pregnancy (Tong et al.,
2013), and prenatal smoking rates in many countries
exceed 20% to 30% (World Health Organization, 2009).
Many biological and biochemical markers have been
shown to be affected by smoking, and some of these have
been linked to adverse outcomes during pregnancy.
The level of the hormone progesterone is associated
with smoking and is a biochemical indicator of potential
for pregnancy complications. During pregnancy, proges-
terone is produced first by the corpus luteum and then
the placenta; this hormone maintains the uterine lining
to carry a fetus to term. When progesterone is low, the
risk of miscarriage or preterm birth (PTB) increases as
the placenta is identified by the maternal immune system
as foreign tissue. Piasek, Blanusa, Kostial, and Laskey
(2001) found that maternal smoking reduced placental
progesterone content, which carries risks for both the
infant and the mother.
Estradiol is another hormone that is crucial during
pregnancy, though its connection to smoking is debated.
At least one study has reported that serum estradiol
levels are not affected by maternal smoking (Windham,
Mitchell, Anderson, & Lasley, 2005), while another
concluded that smoking can reduce the efficacy of the
hormone (Mueck & Seeger, 2005). Although smoking
has long been associated with an antiestrogenic effect,
there is now an established pathway in the liver that
may account for decreased bioavailability at estrogenic
targets (Michnovicz, Hershcopf, Naganuma, Bradlow, &
Fishman, 1986). However, estradiol has been shown to
be crucial for maintaining a pregnancy, and its levels
increase through trimesters (Mazor et al., 1994;
Punnonen & Lukola, 1981). It also serves the important
regulator of progesterone throughout the course of the
pregnancy (Smith et al., 2009; Tal, Taylor, Burney,
Mooney, & Giudice, 2015).
The purpose of this study was to evaluate the associ-
ation of biochemically validated prenatal tobacco use with
serum progesterone and estradiol in the second trimester
of pregnancy, controlling for demographic and personal
factors. We hypothesized that pregnant smokers would
have lower progesterone than their nonsmoking peers,
but we were unsure of association between prenatal
tobacco use and estradiol.
Methods
Design and Sample
This was a secondary analysis of a prospective, multi-
center study evaluating cytokine expression across tri-
mesters in singleton pregnancies. The primary objective
of the original study did not consider assessing the asso-
ciation of biochemically validated tobacco use with
serum progesterone and estradiol during the second
trimester of pregnancy, which is the purpose of this
study. The institutional review boards of the University
of Kentucky and the University of Virginia approved
the original study and the modification for this study.
This secondary analysis is based on the second trimester
assessment of the longitudinal study, as this timepoint
included measurement of the key analysis variables,
namely, validated tobacco use, progesterone, and estra-
diol. Women aged 16 years and older with singleton
pregnancies were recruited by research nurses or nurse
practitioners into the study during the first trimester at a
prenatal care visit to university-affiliated prenatal clinics
in Kentucky and Virginia. Exclusion criteria were history
of diabetes, heart disease, autoimmune disease, or HIV;
indication of drug abuse during the second or third tri-
mesters; diagnosis of sexually transmitted infection; or
multifetal pregnancy or pregnancy incompatibility with
life. Participants were informed of possible risks and
their right to leave the study at any time without penalty,
and 399 women agreed to participate. Upon the comple-
tion of each appointment at which data were collected,
participants were given a $20 gift card. If participants
completed all four appointments, they were given an
additional $20 gift card, for a total of $100.00 in possible
compensation for study participation.
Patients (N¼ 114) were included in this analysis if
serum progesterone, estradiol, and urine cotinine meas-
urements were obtained in the second trimester. Women
on progestogen therapy (17-OHPC or vaginal progester-
one) were excluded. Data were collected from January
2008 to December 2013. Demographics were collected at
a first-trimester prenatal appointment at which time pre-
natal tobacco use was also confirmed via urine cotinine.
Measures
Personal characteristics. Demographic factors included age
(in years) and race or ethnicity (with five options, includ-
ing Hispanic). Given the limited numbers of women in
each racial or ethnic minority, this variable was categor-
ized as ‘‘White or non-Hispanic’’ or ‘‘Other.’’ We also
determined body mass index (BMI) using height and
weight recorded in the baseline (first trimester) evalu-
ation. Gestational age at the time of progesterone and
estradiol assessment (second trimester) was determined
relative to the ultrasound examination conducted in the
first trimester.
Biochemical validation of tobacco use. The baseline (first
trimester) urine samples were tested using NicAlert
strips. NicAlert has been shown to be a valid biochem-
ical indicator of smoking status in adults (Nymox, 2016).
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A score of 3 or higher on this test is indicative of a urine
cotinine value of 100 ng/mL or greater; this cutoff was
used to determine tobacco use. NicAlert cutoffs for
smoking validation are consistent with previously
reported urine cotinine ranges, including among preg-
nant women (Bernert, Harmon, Sosnoff, & McGuffey,
2005; Higgins et al., 2007). The first-trimester cotinine
assessment was used for this measure, both to capture
any prenatal exposure to active smoking and to acknow-
ledge that most women who are still smoking at that
point of their pregnancy continue to do so throughout
the prenatal period; in our study, 86% of those who were
smoking at the first-trimester assessment were still smok-
ing during the second trimester (Ashford et al., 2018).
Hormones. Five cubic centimeters of blood were drawn
into gold top tubes, centrifuged, and transported to
the Reproductive Endocrinology Laboratory at the
University of Kentucky. Serum was frozen until assayed.
Estradiol and progesterone were assayed by a solid-
phase, competitive chemiluminescent enzyme immuno-
assay using an Immulite 1000 (Siemens Healthcare
Diagnostics, Los Angeles, CA) according to the manu-
facturer’s recommendations. Serum and alkaline
phosphatase-labeled hormone were added to antibody-
coated beads which were then incubated at 37C for up
to 70 minutes. Test units were washed after incubation,
alkaline phosphatase substrate was added, and the sam-
ples were incubated at 37C for 10 minutes. Counts per
second for each sample were converted to analyte con-
centrations using stored master curves. The assay sensi-
tivities were as follows: estradiol (15 pg/mL) and
progesterone (0.2 ng/mL). The intraassay and interassay
coefficients of variation were routinely between 5% and
8% and 10% and 13%, respectively.
Biosample data are maintained by the Center for
Clinical and Translational Science at the University of
Kentucky. Inquiries about other data should be directed
to the principal investigator and first author.
Data Analysis
Descriptive statistics, including means and standard
deviations or frequency distributions, were used to sum-
marize the study variables. Multiple regression analysis
was used to test for an association between prenatal
tobacco use and second-trimester hormone levels, con-
trolling for age, BMI, and race or ethnicity; a second set
of models, with one for each outcome, also included ges-
tational age as an additional covariate (Singer, 1998).
This second set of models was considered to determine
if the significant association observed in the initial model
between tobacco use and progesterone would remain sig-
nificant when controlling for gestational age, a known
correlate of progesterone (Tal et al., 2015). In addition,
the second model for estradiol was considered to evalu-
ate whether any of the variables would predict this out-
come; specifically, this model was to test whether the
expected positive association between gestational age
and estradiol would emerge, controlling for the other
variables in the model. Variance inflation factors
gauged the presence of multicollinearity in the regression
models. Data analysis was done using SAS v. 9.4, with
an alpha level of .05 used throughout.
Results
The average age of participants was 26.9 (SD¼ 5.5) and
average BMI was 26.7 (SD¼ 6.9; see Table 1). Most of the
participants were White or non-Hispanic (80%). Nearly
one fifth were biochemically validated as smokers (19%).
The average gestational age at the time of the second
trimester assessment of hormones was 20.4 weeks
(SD¼ 3.1). The average progesterone level was 57.1
(SD¼ 19.3), while mean estradiol was 7.8 (SD¼ 4.9).
Results of the multiple linear regression models are
displayed in Table 2. With age, BMI, race or ethnicity,
and confirmed tobacco use in the model, the overall
regression of progesterone on these variables was signifi-
cant (F¼ 3.12, p¼ .018). These personal factors and pre-
natal tobacco use accounted for 11% of the variability in
second-trimester progesterone. Although progesterone
level was not associated with age or race or ethnicity,
for each one-unit increase in BMI, the average proges-
terone value decreased by more than one-half point (i.e.,
.58 change for each one-unit increase in BMI).
Compared with nonsmokers, active smokers had an
average progesterone level that was more than 10
points lower (i.e., 10.32 difference in progesterone for
Table 1. Descriptive Summary of Demographic Variables,
Smoking Status, and Hormones (N¼ 114).
Mean (SD)
or n (%)
Age 26.9 (5.5)
BMI 26.7 (6.9)
Race or ethnicity
White or non-Hispanic 91 (79.8%)
Other 23 (20.2%)
Prenatal tobacco use
Yes 22 (19.3%)
No 92 (80.7%)
Second trimester gestational age (weeks) 20.4 (3.1)
Progesterone 57.1 (19.3)
Estradiol 7.8 (4.9)
Note. BMI¼ body mass index.
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the comparison of smokers to nonsmokers). When ges-
tational age was added to the model, prenatal tobacco
use became nonsignificant, but both BMI and gestational
age were significant. The overall model was significant
(F¼ 10.6, p< .001), and the R2 for the model with ges-
tational age added was 0.35. The decrease in progester-
one with each one-unit increase in BMI was relatively
consistent between the two models, and for the second
model, the increase in progesterone for each additional
week of gestational age was approximately 3 units.
With age, BMI, and race or ethnicity in the model, the
overall regression of estradiol on these variables was not
significant (F¼ 1.2, p¼ .31). Consistent with a nonsigni-
ficant regression, none of the potential predictors
included in the model were significantly associated with
estradiol level (Table 2). With gestational age added to
the model, the overall model was significant (F¼ 7.2,
p< .001). The only significant predictor was gestational
age, but this and the other variables in the model
accounted for 27% of the variability in estradiol. For
each 1-week increase in gestational age, there was an
average increase in estradiol of 0.67 units. The variance
inflation factors for both sets of models were all less than
2, suggesting that the model parameters were not influ-
enced by multicollinearity.
Discussion
Progesterone was found to be significantly lower
in women who were active smokers compared with
nonsmokers, when measured in the second trimester of
pregnancy. This is consistent with the literature that has
reported lower serum progesterone levels among women
who smoke in early pregnancy (Soldin, Makambi,
Soldin, & O’Mara, 2011; Toriola et al., 2011).
Soldin et al. (2011) further explored the relationship
between tobacco exposure and progesterone and estra-
diol, also confirming lowers levels of both steroids in
early pregnancy.
The found association between BMI and lower
progesterone levels is also consistent with past research.
Goh, He, Allen, Malhotra, and Tan (2016) found
significant differences in serum progesterone in early
pregnancy among underweight, normal weight, over-
weight, and obese women, when adjusting for age, multi-
parity, gestational age, timing of measurement, and,
notably, smoking. Further, smoking has been found to
be associated with higher BMI in White women as early
as adolescence (ages 12–18 years; Young et al., 2015).
It is likely that both smoking and higher BMI, as well
as their combined effects, result in lower serum proges-
terone, which is potentially deleterious to maternal and
fetal health during pregnancy.
Other studies have found a nonlinear relationship
between BMI and estradiol (Ziomkiewicz, Ellison,
Lipson, Thune, & Jasienska, 2008). Rehman, Hussain,
and Faraz (2012) found that obese (BMI5 26) women
had significantly lower estradiol than normal weight
(BMI¼ 18–22.9) women, though overweight women
(BMI¼ 23–25.9) had higher estradiol levels than
normal weight participants. However, Jones et al.
(2013) found a positive relationship between estradiol
and BMI in a sample of postmenopausal women: Over
5 years, decreases in BMI were associated with decreases
in estradiol.
Previous studies have shown higher maternal BMI to
be associated with negative birth outcomes, including
increased prevalence of indicated preterm delivery, as
well as stillbirth, neonatal death, and birth defects
(Koullali, Nijman, Mol, & Pajkrt, 2016; Vasudevan,
Table 2. Tests of Hormone Differences by Prenatal Tobacco Use, Controlling for Demographic Factors (n¼ 107).
Variables in model
Progesterone Estradiol
Est. b (SE b) Std. b p Est. b (SE b) Std. b p
Age 0.176 (0.34) 0.05 .61 0.114 (0.09) 0.13 .20
BMI 0.578 (0.26) 0.21 .028 0.039 (0.07) 0.06 .56
White or non-Hispanic 5.941 (4.59) 0.12 .20 1.872 (1.20) 0.15 .12
Prenatal tobacco use 10.326 (4.88) 0.21 .037 0.980 (1.28) 0.08 .45
Model fit statistics: F¼ 3.1, p¼ .018; R2¼ .11 F¼ 1.2, p¼ .31; R2¼ .05
Age 0.200 (0.29) 0.06 .50 0.086 (0.07) 0.10 .25
BMI 0.554 (0.22) 0.21 .014 0.030 (0.06) 0.05 .60
White or non-Hispanic 2.393 (3.98) 0.05 .55 1.586 (1.03) 0.14 .13
Prenatal tobacco use 5.407 (4.19) 0.11 .20 0.268 (1.17) 0.02 .82
Gestational age 3.050 (0.50) 0.51 <.001 0.672 (0.13) 0.46 <.001
Model fit statistics: F¼ 10.6, p< .001; R2¼ .35 F¼ 7.5, p< .001; R2¼ .27
Note. BMI¼ body mass index; Est.: estimated.
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Renfrew, & McGuire, 2011). Clayborne, Giesbrecht,
Bell, and Tomfohr-Madsen (2017) found that maternal
weight mediated associations between neighborhood
socioeconomic status and both large for gestational age
births and macrosomia, which can necessitate preterm
delivery (Spong et al., 2011). Lower serum progesterone,
especially among women who smoke, is a possible mech-
anism for associations between higher BMI and preterm
birth and related risks.
During pregnancy, estradiol varies with gestational
age and tobacco use. A limited numbers of studies
have explored associations between tobacco use and
estradiol level in pregnant women and women of child-
bearing age. In nonpregnant women, serum estradiol
measured in the follicular phase has been shown to be
significantly higher in women who reported smoking a
pack or more of cigarettes per day when compared with
nonsmokers (Caserta et al., 2013; Zumoff et al., 1990).
Estradiol levels in pregnant smokers have varied effects
based on gestational age. Early in pregnancy, estradiol
levels were significantly depressed in smokers (Soldin
et al., 2011); on the other hand, Petridou et al. (1990)
reported a marginally negative relationship between pre-
natal smoking and estradiol levels in the latter second
trimester. Inconsistencies in measurement of smoking
status, whether verified by cotinine or self-report, could
also contribute to mixed results.
Conclusion
This was among the first studies to prospectively examine
the relationship of confirmed tobacco use during preg-
nancy with serum progesterone and estradiol. This study
provides additional evidence that prenatal tobacco users
may have lower serum progesterone during the second
trimester of pregnancy. This is of particular concern
given the link between depressed serum progesterone
levels and risk for preterm birth. Additional research is
needed to establish best practices on biosample media
(urine, serum) and timing of collection of estradiol to
further evaluate the association between prenatal
tobacco use and estradiol while examining whether any
association may be linked to risk of adverse pregnancy
outcome.
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